National Academies Press: OpenBook
« Previous: 4 Observations and Looking Forward
Suggested Citation:"References." Institute of Medicine. 2012. Ranking Vaccines: A Prioritization Framework: Phase I: Demonstration of Concept and a Software Blueprint. Washington, DC: The National Academies Press. doi: 10.17226/13382.
×

References

Andrus, J. K., V. Dietz, J. W. Fitzsimmons, and C. Castillo-Solorzano. 2006. Accelerating policy, deployment, and access to new and underutilized vaccines in developing countries. Harvard Health Policy Review 7(2):91–101.

Andrus, J. K., C. M. Toscano, M. Lewis, L. Oliveiria, A. M. Ropero, M. Dávila, and J. W. Fitzsimmons. 2007. A model for enhancing evidence-based capacity to make informed policy decisions on the introduction of new vaccines in the Americas: PAHO’s ProVac initiative. Public Health Reports 122(6):811–816.

Barron, F. H., and B. E. Barrett. 1996. The efficacy of SMARTER: Simple multi-attribute rating technique extended to ranking. Acta Psychologica 93(1–3):23–36.

Berry, D. A., K. A. Cronin, S. K. Plevritis, D. G. Fryback, L. Clarke, M. Zelen, J. S. Mandelblatt, A. Y. Yakovlev, J. D. F. Habbema, and E. J. Feuer. 2005. Effect of screening and adjuvant therapy on mortality from breast cancer. New England Journal of Medicine 353(17):1784–1792.

Braithwaite, R., D. Meltzer, J. King Jr, D. Leslie, and M. S. Roberts. 2008. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Medical Care 46(4):349–356.

Burchett, H. E. D., S. Mounier-Jack, U. K. Griffiths, and A. J. Mills. 2011. National decision-making on adopting new vaccines: A systematic review. Health Policy and Planning 27(Suppl 2):ii62–ii76.

Commission on Macroeconomics and Health. 2001. Macroeconomics and health: Investing in health for economic development. Report of the Commission on Macroeconomics and Health. Available at http://whqlibdoc.who.int/publications/2001/924154550x.pdf (accessed April 16, 2012).

Daniels, N. 2007. Just health: Meeting health needs fairly. Cambridge: Cambridge University Press.

Suggested Citation:"References." Institute of Medicine. 2012. Ranking Vaccines: A Prioritization Framework: Phase I: Demonstration of Concept and a Software Blueprint. Washington, DC: The National Academies Press. doi: 10.17226/13382.
×

Dyer, J. 1990. Remarks on the analytic hierarchy process. Management Science 36:249–258.

Edwards, W. 1979. Multiattribute utility measurement: Evaluating desegregation plans in a highly political context. In Evaluating interventions: Pros and cons, edited by R. Perloff. Beverly Hills, CA: Sage. Pp. 13–54.

Edwards, W., and F. H. Barron. 1994. SMARTS and SMARTER: Improved simple methods for multiattribute utility measurement. Organizational Behavior and Human Decision Processes 60(3):306–325.

Edwards, W. and J. R. Newman. 1982. Multiattribute evaluation. Beverly Hills, CA: Sage.

Epstein, J. M., J. Parker, D. Cummings, and R. A. Hammond. 2008. Coupled contagion dynamics of fear and disease: Mathematical and computational explorations. PLoS One 3(12):e3955.

Feeny, D., G. Torrance, and W. Furlong. 1996. Health Utilities Index. In Quality of life and pharmacoeconomics in clinical trials, 2nd ed., edited by B. Spilker. Philadelphia: Lippincott—Raven Press. Pp. 239–252.

Fenwick, E., K. Claxton, and M. Sculpher. 2001. Representing uncertainty: The role of cost-effectiveness acceptability curves. Health Economics 10(8):779–787.

Field, R. I., and A. L. Caplan. 2012. Evidence-based decision making for vaccines: The need for an ethical foundation. Vaccine 30(6):1009–1013.

Fox-Rushby, J. A., and K. Hanson. 2001. Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. Health Policy Plan 16(3):326–331.

Fryback, D. G. 2009. United States National Health Measurement Study, 2005–2006. In [Computer file]. National Archive of Computerized Data on Aging: Inter-University Consortium for Political and Social Research.

Fryback, D. G., N. C. Dunham, M. Palta, J. Hanmer, J. Buechner, D. Cherepanov, S. Herrington, R. D. Hays, R. M. Kaplan, and T. G. Ganiats. 2007. U.S. norms for six generic health-related quality-of-life indexes from the National Health Measurement Study. Medical Care 45(12):1162–1170.

Fryback, D. G., M. Palta, D. Cherepanov, D. Bolt, and J. S. Kim. 2010. Comparison of 5 health-related quality-of-life indexes using item response theory analysis. Medical Decision Making 30(1):5–15.

Garber, A., and C. Phelps. 1997. Economic foundations of cost-effectiveness analysis. Journal of Health Economics 16(1):1–31.

Gates, B. 2010. The decade of vaccines. In The Financial Times Blog, http://tinyurl.com/6o7fd92 (accessed March 1, 2012).

Suggested Citation:"References." Institute of Medicine. 2012. Ranking Vaccines: A Prioritization Framework: Phase I: Demonstration of Concept and a Software Blueprint. Washington, DC: The National Academies Press. doi: 10.17226/13382.
×

GAVI Alliance. 2010. Investing in immunisation through the GAVI alliance: The evidence base. Geneva: GAVI Alliance.

Gold, M. R., D. L. Patrick, G. W. Torrance, D. G. Fryback, D. C. Hadorn, M. S. Kamlet, N. Daniels, and M. C. Weinstein. 1996. Identifying and valuing outcomes. In Cost effectiveness in health and medicine, edited by M. R. Gold, J. E. Siegel, L. B. Russell, and M. C. Weinstein. New York: Oxford University Press. Pp. 82–134.

Gold, M. R., D. Stevenson, and D. G. Fryback. 2002. HALYs and QALYs and DALYs, Oh my: Similarities and differences in summary measures of population health. Annual Review of Public Health 23(1):115–134.

Government of India. 2011. National vaccine policy. New Delhi: Ministry of Health and Family Welfare.

Greco, M., and L. Hessel. 2008. Development and supply of vaccines: An industry perspective. In New generation vaccines, 4th ed., edited by M. Levine, G. Dougan, M. Good, M. Liu, G. Nabel, J. Nataro and R. Rappuoli. New York: Informa Healthcare. Pp. 79–90.

HHS (U.S. Department of Health and Human Services). 2011. 2010 National vaccine plan. Washington, DC: U.S. Department of the Health and Human Services.

IOM (Institute of Medicine). 1985. New vaccine development: Establishing priorities. Volume I, diseases of importance in the United States. Washington, DC: National Academy Press.

IOM. 1986. New vaccine development: Establishing priorities. Volume II, diseases of importance in developing countries. Washington, DC: National Academy Press.

IOM. 2000. Vaccines for the 21st century: A tool for decisionmaking. Washington, DC: National Academy Press.

Jefferson, T. 1806. A tribute of gratitude: To Edward Jenner. In Thomas Jefferson: Letters 1743-1826. Charlottesville, VA: Electronic Text Center, University of Virginia Library.

Jenner, E. 1801. On the origin of the vaccine inoculation. London: D.N. Shury.

Keefer, D. L., C. W. Kirkwood, and J. L. Corner. 2004. Perspective on decision analysis applications, 1990–2001. Decision Analysis 1(1):4–22.

Keeler, E. B., and S. Cretin. 1983. Discounting of life-saving and other non-monetary effects. Management Science 29(3):300–306.

Keeney, R., and H. Raiffa. 1976. Decisions with multiple objectives: Preferences and value tradeoffs. New York: John Wiley & Sons, Inc.

Keeney, R., and G. Smith. 1982. Structuring objectives for evaluating possible nuclear material control and accounting regulations. IEEE Transactions on Systems, Man and Cybernetics 12(6):743–750.

Suggested Citation:"References." Institute of Medicine. 2012. Ranking Vaccines: A Prioritization Framework: Phase I: Demonstration of Concept and a Software Blueprint. Washington, DC: The National Academies Press. doi: 10.17226/13382.
×

Keeney R, and D. von Winterfeldt. 2007. Practical value models. In Advances in decision analysis, edited by W. Edwards, R. F. Miles, and D. von Winterfeldt. New York: Cambridge University Press. Pp. 232–252.

Keeney, R., and D. von Winterfeldt. 2011. A value model for evaluating homeland security decisions. Risk Analysis 31(9):1470–1487.

Keeney, R., T. McDaniels, and V. Ridge-Cooney. 1996. Using values in planning wastewater facilities for metropolitan seattle. Journal of the American Water Resources Association 32(2):293–303.

Keja, K., C. Chan, G. Hayden, and R. H. Henderson. 1988. Expanded programme on immunization. World Health Statistics Quarterly. Rapport Trimestriel de Statistiques Sanitaires Mondiales 41(2):59–63.

Knutti, R., R. Furrer, C. Tebaldi, J. Cermak, and G. A. Meehl. 2010. Challenges in combining projections from multiple climate models. Journal of Climate 23(10):2739–2758.

Krantz, D. L,, D. Luce, P. Suppes, A. Tversky, 1971. Foundations of Measurement, New York: Academic Press.

Luo, N., J. A. Johnson, J. W. Shaw, D. Feeny, and S. J. Coons. 2005. Self-reported health status of the general adult U.S. population as assessed by the EQ-5D and Health Utilities Index. Medical Care 43(11):1078–1086.

Luo, N., J. A. Johnson, J. W. Shaw, and S. J. Coons. 2009. Relative efficiency of the EQ-5D, HUI2, and HUI3 index scores in measuring health burden of chronic medical conditions in a population health survey in the United States. Medical Care 47(1):53–60.

Manning, W. G., D. Fryback, and M. Weinstein. 1996. Reflecting uncertainty in cost-effectiveness analysis. In Cost-effectiveness in health and medicine, edited by M. R. Gold, J. E. Siegel, L. B. Russell and M. C. Weinstein. New York: Oxford University Press. Pp. 247–275.

Mathers, C. D., A. D. Lopez, and C. J. L. Murray. 2006. The burden of disease and mortality by condition: Data, methods, and results for 2001. In Global burden of disease and risk factors, edited by A. D. Lopez, C. D. Mathers, M. Ezzati, D. T. Jamison, and C. J. L. Murray. Washington, DC: World Bank. Pp. 45–93.

McNeil, D. 2012. Bill Gates donates $750 million to shore up disease-fighting fund. New York Times, January 26.

Meckley, L. M., D. Greenberg, J. T. Cohen, and P. J. Neumann. 2010. The adoption of cost-effectiveness acceptability curves in cost-utility analyses. Medical Decision Making 30(3):314–319.

Molinari, N. A., I. R. Ortega-Sanchez, M. L. Messonnier, W. W. Thompson, P. M. Wortley, E. Weintraub, and C. B. Bridges. 2007. The annual impact of seasonal influenza in the US: Measuring disease burden and costs. Vaccine 25(27):5086–5096.

Suggested Citation:"References." Institute of Medicine. 2012. Ranking Vaccines: A Prioritization Framework: Phase I: Demonstration of Concept and a Software Blueprint. Washington, DC: The National Academies Press. doi: 10.17226/13382.
×

Murray, C. J. L., and A. D. Lopez. 1996. The global burden of disease: A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Vol. 1, Global burden of disease and injury series. Cambridge, MA: Harvard School Public Health/WHO/World Bank.

Murray, C. J. L., and A. D. Lopez. 2000. Progress and directions in refining the global burden of disease approach: A response to Williams. Health Economics 9(1):69–82.

Phelps, C. E., and A. I. Mushlin. 1988. Focusing technology assessment using medical decision theory. Medical Decision Making 8(4):279–289.

Plotkin, S., S. Sepe, and M. Myers. 2000. Institute of Medicine report: “Vaccines for the 21st century,” analysis and action plan for the National Vaccine Advisory Committee; prepared for NVAC Subcommittee on Future Vaccines. http://www.hhs.gov/nvpo/nvac/vaccines21cer.html (accessed January 26, 2012).

Poland, G. A., and E. K. Marcuse. 2011. Developing vaccine policy: Attributes of “just policy” and a proposed template to guide decision and policy making. Vaccine 29(44):7577–7578.

Ramsey, S., R. Willke, A. Briggs, R. Brown, M. Buxton, A. Chawla, J. Cook, H. Glick, B. Liljas, D. Petitti, and S. Reed. 2005. Good research practices for cost-effectiveness analysis alongside clinical trials: The ISPOR RCT—CEA Task Force Report. Value Health 8(5):521–533.

Rappuoli, R., and A. Aderem. 2011. A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 473(7348):463–469.

Rappuoli, R., H. Miller, and S. Falkow. 2002. The intangible value of vaccination. Science 297(5583):937–939.

Rappuoli, R., C. Mandl, S. Black, and E. De Gregorio. 2011. Vaccines for the twenty-first century society. Nature Reviews Immunology 11(12): 865–872.

Rardin, R. 1997. Optimization in operations research. Upper Saddle River, NJ: Prentice Hall.

Saaty, T., 1987. Concepts, theory and techniques: Rank generation, preservation, and reversal in the Analytic Hierarchy Process. Decision Sciences 18:157–177.

Stern, A., and H. Markel. 2005. The history of vaccines and immunization: Familiar patterns, new challenges. Health Affairs 24(3):611–621.

von Winterfeldt, D., and W. Edwards. 1986. Decision analysis and behavioral research. Vol. 1. New York: Cambridge University Press.

Weinstein, M. C. 2008. How much are Americans willing to pay for a quality-adjusted life year? Medical Care 46(4):343–345.

Suggested Citation:"References." Institute of Medicine. 2012. Ranking Vaccines: A Prioritization Framework: Phase I: Demonstration of Concept and a Software Blueprint. Washington, DC: The National Academies Press. doi: 10.17226/13382.
×

WHO (World Health Organization). 2003. Making choices in health: WHO guide to cost-effectiveness analysis. Edited by T. Tan-Torres Edejer, R. Baltussen, T. Adam, R. Hutubessy, A. Acharya, D. B. Evans, and C. J. L. Murray. Geneva: World Health Organization.

WHO. 2004. Global burden of disease 2004 update: Disability weights for diseases and conditions. Geneva: World Health Organization.

WHO. 2006. Global immunization vision and strategy. www.who.int/immunization/givs/en/index.html.

WHO. 2010. The Initiative for Vaccine Research, strategic plan 2010-2020. Geneva: Initiative for Vaccine Research, Department of Immunization, Vaccines and Biologicals.

Suggested Citation:"References." Institute of Medicine. 2012. Ranking Vaccines: A Prioritization Framework: Phase I: Demonstration of Concept and a Software Blueprint. Washington, DC: The National Academies Press. doi: 10.17226/13382.
×
Page 115
Suggested Citation:"References." Institute of Medicine. 2012. Ranking Vaccines: A Prioritization Framework: Phase I: Demonstration of Concept and a Software Blueprint. Washington, DC: The National Academies Press. doi: 10.17226/13382.
×
Page 116
Suggested Citation:"References." Institute of Medicine. 2012. Ranking Vaccines: A Prioritization Framework: Phase I: Demonstration of Concept and a Software Blueprint. Washington, DC: The National Academies Press. doi: 10.17226/13382.
×
Page 117
Suggested Citation:"References." Institute of Medicine. 2012. Ranking Vaccines: A Prioritization Framework: Phase I: Demonstration of Concept and a Software Blueprint. Washington, DC: The National Academies Press. doi: 10.17226/13382.
×
Page 118
Suggested Citation:"References." Institute of Medicine. 2012. Ranking Vaccines: A Prioritization Framework: Phase I: Demonstration of Concept and a Software Blueprint. Washington, DC: The National Academies Press. doi: 10.17226/13382.
×
Page 119
Suggested Citation:"References." Institute of Medicine. 2012. Ranking Vaccines: A Prioritization Framework: Phase I: Demonstration of Concept and a Software Blueprint. Washington, DC: The National Academies Press. doi: 10.17226/13382.
×
Page 120
Next: Appendix A: Mathematical Functions »
Ranking Vaccines: A Prioritization Framework: Phase I: Demonstration of Concept and a Software Blueprint Get This Book
×
Buy Paperback | $60.00 Buy Ebook | $48.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

As a number of diseases emerge or reemerge thus stimulating new vaccine development opportunities to help prevent those diseases, it can be especially difficult for decision makers to know where to invest their limited resources. Therefore, it is increasingly important for decision makers to have the tools that can assist and inform their vaccine prioritization efforts.

In this first phase report, the IOM offers a framework and proof of concept to account for various factors influencing vaccine prioritization-demographic, economic, health, scientific, business, programmatic, social, policy factors and public concerns. Ranking Vaccines: A Prioritization Framework describes a decision-support model and the blueprint of a software-called Strategic Multi-Attribute Ranking Tool for Vaccines or SMART Vaccines. SMART Vaccines should be of help to decision makers. SMART Vaccines Beta is not available for public use, but SMART Vaccines 1.0 is expected to be released at the end of the second phase of this study, when it will be fully operational and capable of guiding discussions about prioritizing the development and introduction of new vaccines.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!